{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:26Z","timestamp":1792001906846,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ctrv.2025.103049","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:27:48Z","timestamp":1763346468000},"page":"103049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-8754","authenticated-orcid":false,"given":"D.","family":"Miliziano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sciortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Manglaviti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ganzinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lopez-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Proto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Lo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctrv.2025.103049_b0005","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103049_b0010","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic therapy in advanced thymic epithelialtumors: insights from the RYTHMIC prospective cohort","volume":"13","author":"Merveilleux du Vignaux","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103049_b0015","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet\u2014a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103049_b0020","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103049_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102014","article-title":"Thymic epithelial tumors: from biology to treatment","volume":"86","author":"Conforti","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103049_b0030","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jtho.2023.09.001","volume":"18","author":"Marom","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103049_b0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2021.11.028","article-title":"Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network","volume":"162","author":"Petat","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103049_b0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103049_b0045","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg Today"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103049_b0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2014.05.010","article-title":"Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study","volume":"85","author":"Lattanzio","year":"2014","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103049_b0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2613.2011.00777.x","article-title":"Platelet\u2010derived growth factor and platelet\u2010derived growth factor receptor\u2010\u03b1 expression in the normal human thymus and thymoma","volume":"92","author":"Cimpean","year":"2011","journal-title":"Int J Exp Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103049_b0060","first-page":"4057","article-title":"Expression and mutational status of PDGFR in thymic tumours","volume":"29","author":"Meister","year":"2009","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103049_b0065","doi-asserted-by":"crossref","first-page":"17359","DOI":"10.1038\/s41598-019-53671-8","article-title":"Follistatin impacts Tumor angiogenesis and outcome in Thymic epithelial Tumors","volume":"9","author":"Janik","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103049_b0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103049_b0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103049_b0080","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jtho.2023.04.009","article-title":"STYLE (NCT03449173): a phase 2 trial of sunitinib in patients with type B3 Thymoma or Thymic carcinoma in second and further lines","volume":"18","author":"Proto","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103049_b0085","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40262-016-0404-5","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor","volume":"55","author":"Khosravan","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103049_b0090","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103049_b0095","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/j.jtho.2018.08.297","article-title":"OA11.05 phase II study of sunitinib in patients with thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC Trial)","volume":"13","author":"Kim","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103049_b0100","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/j.jtho.2016.11.332","article-title":"OA18.02 evaluation of a modified dosing regimen(2-weeks on\/1-week off) of sunitinib as part of a phase II trial in thymic carcinoma","volume":"12","author":"Rajan","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103049_b0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2022.07.009","article-title":"Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: a retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group","volume":"174","author":"Antonarelli","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103049_b0110","unstructured":"\u201cSunitinib for Advanced Thymus Cancer Following Earlier Treatment. Results Posted. [(accessed on 1 October 2023)]; Available online: https:\/\/clinicaltrials.gov\/study\/NCT01621568?tab=results \u201d."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103049_b0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000492533","article-title":"Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma","volume":"7","author":"Kudo","year":"2018","journal-title":"Liver Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103049_b0120","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103049_b0125","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103049_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107557","article-title":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: results from the multicenter, phase 2 REMORA trial","volume":"191","author":"Niho","year":"2024","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103049_b0135","first-page":"S246","article-title":"424P: Real-world data of lenvatinib in patients with thymic epithelial tumors (TETs)","volume":"20","author":"Guti\u00e9rrez","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103049_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105301","article-title":"Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings","volume":"10","author":"Takagi","year":"2025","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103049_b0145","first-page":"S353","article-title":"Clinical activity of lucitanib in advanced thymic epithelial tumours","volume":"10","author":"Besse","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103049_b0150","doi-asserted-by":"crossref","first-page":"S1632","DOI":"10.1016\/j.annonc.2024.10.658","article-title":"625O Efficacy and safety of lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: a randomized, double-blind, placebo-controlled multicenter phase II trial","volume":"35","author":"Fang","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103049_b0155","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/cncr.33990","article-title":"Resound Trial: a phase 2 study of regorafenib in patients with thymoma (type B2\u2010B3) and thymic carcinoma previously treated with chemotherapy","volume":"128","author":"Perrino","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.103049_b0160","doi-asserted-by":"crossref","unstructured":"\u201cLee S-H, Ahn M-J, Park S, Cho E-K, Shim B, Ko YH, et al. LBA105 \u2013 A phase II, open-label, single-arm, multi-center study of rivoceranib in patients with metastatic thymic epithelial tumor, KCSG LU23-09 (THRIVE). In: ESMO Congress 2025; 17\u201321 October 2025; Berlin, Germany. Ann Oncol. 2025;36(Suppl 5):LBA105.\u201d.","DOI":"10.1016\/j.annonc.2025.09.122"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103049_b0165","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/1759-7714.12755","article-title":"EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: R esponse to apatinib and clinical outcomes","volume":"9","author":"Yudong","year":"2018","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103049_b0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12916-022-02361-w","article-title":"Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103049_b0175","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1111\/1759-7714.13658","article-title":"Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: a case report and literature review","volume":"11","author":"Zuo","year":"2020","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103049_b0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12885-022-10448-z","article-title":"The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma","volume":"23","author":"Guan","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103049_b0185","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2174\/1574892818666221122114753","article-title":"The efficacy and safety of anlotinib alone and in combination with other drugs in previously treated advanced thymic epithelia tumors: a retrospective analysis","volume":"18","author":"Li","year":"2023","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2025.103049_b0190","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J. Clinical Oncol."},{"issue":"2","key":"10.1016\/j.ctrv.2025.103049_b0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12032-021-01620-9","article-title":"Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors","volume":"39","author":"Wang","year":"2022","journal-title":"Med Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103049_b0200","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto","year":"2024","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103049_b0205","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103049_b0210","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103049_b0215","article-title":"S1701, a randomized phase 2 trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma","volume":"5","author":"Tsao","year":"2024","journal-title":"JTO Clin Res Rep"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103049_b0220","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103049_b0225","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103049_b0230","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103049_b0235","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103049_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","year":"2023","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103049_b0245","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2025.103049_b0250","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2025.103049_b0255","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103049_b0260","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103049_b0265","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1470-2045(25)00300-6","article-title":"Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial","volume":"26","author":"Remon","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103049_b0270","article-title":"A phase 1\/2 study to evaluate the safety and activity of nivolumab in combination with vorolanib, a vascular endothelial growth factor tyrosine kinase inhibitor, in patients with refractory thoracic tumors","volume":"5","author":"Beckermann","year":"2024","journal-title":"JTO Clin Res Rep"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:52:10Z","timestamp":1764143530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":54,"alternative-id":["S0305737225001719"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103049","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103049"}}